The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 37, No. 2, pp. 216-219. DOI 10.1345/aph.1C233
© 2003 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McCarthy, M. W
Right arrow Articles by Kockler, D. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCarthy, M. W
Right arrow Articles by Kockler, D. R

Clopidogrel-Associated Leukopenia

Michelle W McCarthy, PharmD

Drug Information Specialist, Department of Pharmacy Services, University of Virginia Health System, Charlottesville, VA

Denise R Kockler, PharmD

Director, Drug Information Services, Virginia Commonwealth University, Medical College of Virginia Hospitals, Richmond, VA

Reprints: Michelle W McCarthy PharmD, Department of Pharmacy Services, University of Virginia Health System, PO Box 800674, Charlottesville, VA 22908-0674, FAX 434/982-1682, E-mail mm4tm{at}virginia.edu

OBJECTIVE: To report a case of leukopenia in a patient receiving clopidogrel following intracoronary stent placement.

CASE SUMMARY: A 58-year-old white man presented to the emergency department (ED) with fever and chills. Seven days prior to presentation, he underwent intracoronary stent placement and clopidogrel 75 mg once daily was initiated. In the ED, laboratory evaluation revealed leukopenia with negative blood and urine cultures. The patient was released but returned the following day with fever and sweating. Infectious complications were ruled out, and clopidogrel was discontinued. Leukopenia resolved within 7 days, and the patient has experienced no further hematologic complications. Based on the Naranjo probability scale, the leukopenia was rated as a probable reaction to clopidogrel.

DISCUSSION: Ticlopidine and clopidogrel are the 2 commercially available thienopyridine antiplatelet agents. Risk of myelotoxicity with ticlopidine is well known and requires frequent hematologic monitoring. Clopidogrel is better tolerated, less toxic, and has more extensive indications, including use in acute coronary syndrome. These factors have resulted in the replacement of ticlopidine by clopidogrel. The 4 previously published reports of clopidogrel-associated white blood cell (WBC) toxicity are described. The mechanism of myelotoxicity with clopidogrel is not known.

CONCLUSIONS: Better tolerability, reduced toxicity (particularly hematologic), and the convenience of once-daily dosing have resulted in the replacement of ticlopidine with clopidogrel. WBC toxicity associated with clopidogrel therapy is very infrequent and has occurred weeks to months following therapy initiation. Clinicians should be aware of the potential for this adverse effect.

Key Words: clopidogrel, leukopenia

Published Online, December 30, 2002. www.theannals.com, DOI




homecopy help contact us subscription past issues search current issue
Copyright © 2003 by Harvey Whitney Books Company.